MedTrace Logo

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

NCT03310580 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2019-12-23

Study results available
· View outcomes & findings →

Summary

To test the safety and effectiveness of AR-13324 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in US.

Conditions

  • Primary Open Angle Glaucoma or Ocular Hypertension

Interventions

DRUG

AR-13324 Ophthalmic Solution 0.02%

Administered to each eye, once daily (QD) in the evening (PM) for 28 days

DRUG

AR-13324 Ophthalmic Solution 0.04%

Administered to each eye, once daily (QD) in the evening (PM) for 28 days

DRUG

AR-13324 Ophthalmic Solution Placebo

Administered to each eye, once daily (QD) in the evening (PM) for 28 days

Sponsors & Collaborators

  • Aerie Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Nancy Ramirez-Davis · Aerie Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-15
Primary Completion
2018-10-25
Completion
2018-10-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03310580 on ClinicalTrials.gov